PMID

Data

Article Title

Organization

Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.

Merck Research Laboratories

Discovery of a novel Kv7 channel opener as a treatment for epilepsy.

Pfizer

Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.

Astrazeneca

Prediction of Thorough QT study results using action potential simulations based on ion channel screens.

University Of Oxford

GPR103 antagonists demonstrating anorexigenic activity in vivo: design and development of pyrrolo[2,3-c]pyridines that mimic the C-terminal Arg-Phe motif of QRFP26.

Astrazeneca

Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.

Vanderbilt University Medical Center

N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

TBA

MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.

Merck Research Laboratories

Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.

Abbott Laboratories

Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.

Merck

Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.

Merck

Synthesis and activity of novel and selective I(Ks)-channel blockers.

Aventis Pharma Deutschland

Development of Chemical Entities Endowed with Potent Fast-Killing Properties against

Glaxosmithkline

Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.

TBA

Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.

Astrazeneca

Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition.

Merck

Neuroactive Steroids. 2. 3?-Hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5?-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (?-Aminobutyric Acid)

Sage Therapeutics

Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88

Astrazeneca